It always seems impossible until it's done.
Every weekday, we hand you a mad startup idea! What you do with it is up to you.
✅ 4 sections ⏱️ 4 minutes 🚫 No fluff.
💡 Mad Idea • 📈 Mad Trends • 🛠 Mad Hack • 📰 Mad News
Mad Idea of the Day
DAAVA!! ⚖️
₹26,000 CRORE OF HEALTH INSURANCE CLAIMS WERE REJECTED IN A SINGLE YEAR. UP TO A THIRD WERE WRONGLY DENIED. ALMOST EVERYONE JUST GAVE UP.
The Challenge: 🏥 In FY24, Indian insurers rejected health claims worth ₹26,037 crore — and IRDAI's own data shows 20–30% of rejected claims get reversed the moment a policyholder pushes back. The catch: a free Insurance Ombudsman exists, awards up to ₹50 lakh, and its ruling is binding on the insurer — but 90% of Indians don't know it exists or how to use it. So when a family's mediclaim is rejected over a "pre-existing disease" technicality after the patient is already discharged, they swallow the loss. The system to fight back is free and stacked in the policyholder's favour. Why has no one made it usable?
The Solution: DAAVA — a success-fee claim-recovery platform ⚖️. Upload your rejection letter and policy. DAAVA's engine reads the exact clause cited, pulls the relevant IRDAI circular, builds your case, and runs it through the full ladder — grievance officer, Bima Bharosa, then the Ombudsman — with the paperwork done for you. You pay nothing unless the money comes back. The wedge is health mediclaim, where rejections are highest and the emotional stakes are rawest. PolicyBazaar sells you the policy. DAAVA makes the policy actually pay.
Business Model: 💰
18% success fee on every rupee recovered — no recovery, no charge
₹499 upfront claim-review (refundable if we take the case): rejection analysis + win-odds
B2B: hospitals and employers offer DAAVA as a claims-support benefit to patients and staff
Exit Strategy: 🚀 5 lakh claims recovered a year by FY30, ₹400 Cr revenue from success fees. Likely acquirers: an insurtech like PB Fintech or Acko wanting a trust halo, a hospital chain, or a legal-tech platform scaling consumer redressal.
Mad Trends: India's religion-tech wave is here 🕉
Investors have fallen in love with hospitals that do exactly one thing. 🩺
The Shift: The era of the sprawling multi-speciality hospital is giving way to focused, single-speciality chains that go deep on one problem and scale it nationally.
The Trend: Hoola Health, founded by the team behind BabyMD, raised $5 million led by Peak XV's Surge in June 2026 to build a dedicated paediatric clinic chain. It sits inside a clear pattern — Dr Agarwals in eye care, Indira IVF in fertility, NephroPlus in dialysis, and Rainbow in children's hospitals have all shown that owning one speciality end-to-end builds trust, repeat visits, and pricing power that a general hospital never gets.
The Drivers:
👨⚕️ Workforce: single-speciality formats need fewer specialists per site, making tier-2 expansion viable
📊 Market Size: India's healthcare delivery market is projected to cross ₹18 lakh Cr by FY30
🎯 Concentration: eye, fertility, dialysis, and mother-and-child chains now attract the bulk of healthcare PE money
🔥 When the focused chain beats the general hospital on trust and economics — which speciality gets its breakout national brand next?
🛠 Mad Hack
The Wrong Start: When Mukesh Bansal launched Myntra in 2007, it wasn't a fashion company at all. It sold personalised gifts — printed mugs, t-shirts, mouse pads — in a clunky model that was going nowhere. A novelty-gifting site in a tiny market, burning time and money with no real path to scale.
The Pivot: Around 2011, Bansal made a brutal call: kill the gifting business entirely and reinvent Myntra as a pure fashion e-commerce platform. He bet everything on branded apparel, deep discovery, and a catalogue of hundreds of brands — a complete change of identity for the company he'd already spent four years building.
The Payoff: Myntra became India's number-one fashion e-commerce platform and was acquired by Flipkart in 2014 for around ₹2,000 crore. Bansal went on to co-found Cult.fit, today India's largest fitness chain. 💪
🎯 The Builder Lesson: If the thing you started isn't working, have the nerve to kill the product — not the company.
🍺 Mad News Today
💼 Curefoods shelves ₹800 Cr IPO as mutual funds reject ₹4,000 Cr valuation amid market volatility — Cloud kitchen dream, deferred.
🏢 Incuspaze acquires iKeva in a 100% buyout, deepening its southern-market presence — Flex-workspace consolidation rolls on.